| Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting AP Abernethy, A Arunachalam, T Burke, C McKay, X Cao, R Sorg, ... PloS one 12 (6), e0178420, 2017 | 96 | 2017 |
| Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study DH Lee, MS Tsao, KO Kambartel, H Isobe, MS Huang, CH Barrios, ... PLoS One 13 (8), e0202865, 2018 | 70 | 2018 |
| Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis AM Frederickson, S Arndorfer, I Zhang, M Lorenzi, R Insinga, ... Immunotherapy 11 (5), 407-428, 2019 | 60 | 2019 |
| Systemic therapy treatment patterns in patients with advanced non‐small cell lung cancer (NSCLC): PI V OTAL study J De Castro, P Tagliaferri, VCC De Lima, S Ng, M Thomas, ... European journal of cancer care 26 (6), e12734, 2017 | 50 | 2017 |
| Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with … MA Bittoni, A Arunachalam, H Li, R Camacho, J He, Y Zhong, ... Clinical lung cancer 19 (5), e629-e645, 2018 | 49 | 2018 |
| Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for Medicare patients with advanced non–small … A Arunachalam, H Li, MA Bittoni, R Camacho, X Cao, Y Zhong, ... Clinical Lung Cancer 19 (5), e783-e799, 2018 | 41 | 2018 |
| Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study DH Lee, H Isobe, H Wirtz, SB Aleixo, P Parente, F de Marinis, M Huang, ... BMC Health Services Research 18, 1-16, 2018 | 21 | 2018 |
| Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan H Isobe, K Mori, K Minato, H Katsura, K Taniguchi, A Arunachalam, ... Lung Cancer: Targets and Therapy, 191-206, 2017 | 20 | 2017 |
| Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis A Arunachalam, I Zhang, B Zhao, AM Frederickson, MC Pietanza Lung Cancer 176, 132-139, 2023 | 8 | 2023 |
| Real-world treatment patterns and outcomes of first-line immunotherapy among patients with advanced nonsquamous Nsclc harboring Braf, Met, or Her2 alterations MC Garassino, S Oskar, A Arunachalam, K Zu, YH Kao, C Chen, W Meng, ... JTO Clinical and Research Reports 4 (10), 100568, 2023 | 5 | 2023 |
| Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non–Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET, or RET Alterations: A Systematic … KG Akers, S Oskar, B Zhao, AM Frederickson, A Arunachalam Journal of Immunotherapy 47 (4), 128-138, 2024 | 4 | 2024 |
| Event-free survival as a predictor of overall survival and recurrence burden of patients with non–small cell lung cancer receiving neoadjuvant therapy J Donington, X Hu, S Zhang, Y Song, A Arunachalam, D Chirovsky, C Gao, ... The Journal of thoracic and cardiovascular surgery 168 (4), 1261-1269. e1, 2024 | 3 | 2024 |
| Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung … JD Spicer, MC Garassino, H Wakelee, M Liberman, T Kato, M Tsuboi, ... The Lancet 404 (10459), 1240-1252, 2024 | 3 | 2024 |
| Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel SS Moser, L Apter, A Arunachalam, T Burke, V Shalev, G Chodick, ... Immunotherapy 13 (10), 851-861, 2021 | 3 | 2021 |
| Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung … MC Garassino, HA Wakelee, J Spicer, M Liberman, T Kato, M Tsuboi, ... Journal of Clinical Oncology 42 (16_suppl), 8012-8012, 2024 | 2 | 2024 |
| Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings K Zu, A Arunachalam, A Hohlbauch, M Silver, N Robert Immunotherapy 15 (16), 1375-1387, 2023 | 1 | 2023 |
| P63. 05 Treatment pattern in small cell lung cancer: a real-world observational study in the era of immune checkpoint inhibitors K Zu, A Arunachalam, S Macdonald, Y Wang, K Wells, S Oliveria, ... Journal of Thoracic Oncology 16 (10), S1184, 2021 | 1 | 2021 |
| PCN41 Cost-Effectiveness of Pembrolizumab in Combination with Chemotherapy in the 1ST LINE Treatment of Metastatic NSCLC in Taiwan R Insinga, A Arunachalam, S Lei, YJ Shao, SC Tan, C Spiteri Value in Health Regional Issues 22, S12, 2020 | 1 | 2020 |
| PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE C Chouaid, L Bensimon, A Millier, E Clay, R Insinga, A Arunachalam, ... Value in Health 22, S458, 2019 | 1 | 2019 |
| PCN193 cost-effectiveness analysis of pembrolizumab in combination with platinum chemotherapy and pemetrexed for previously untreated patients with metastatic non-squamous non … T Harding, R Insinga, H Dawson, BE Bates, A Arunachalam, ... Value in Health 22, S473, 2019 | 1 | 2019 |
